Physician profile
Stacey Jane Howell
NPI 1609290774
$78,806.40
in general payments reported to CMS, 2019-2025
28 companies · $8,534 in 2025
The $8,534 reported for 2025 was more than what 77% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25K · 2022: $35K · 2023: $5,520 · 2024: $4,598 · 2025: $8,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,005 · Consulting Fee: $6,000 · Travel and Lodging: $3,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,005.10 |
| Consulting Fee | $6,000.00 |
| Travel and Lodging | $3,647.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $40,312.25 | 2021-2025 | Ensite Precision, Aveir, Ensite |
| Medtronic, INC. | $26,462.13 | 2021-2024 | Micra, Selectsecure |
| Biosense Webster, INC. | $6,929.90 | 2021-2025 | Carto 3, Qdot Micro Catheter, Octaray Mapping Catheter |
| Medical Device Business Services, INC. | $1,875.00 | 2024-2025 | Carto 3 |
| Biotronik INC. | $479.91 | 2022-2024 | Edora 8 Dr-T, Biomonitor, Amvia Edge |
| Boston Scientific Corporation | $429.69 | 2023-2025 | Emblem Mri S-Icd, General - Therapies, Wavewriter Alpha Prime 16 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $305.09 | 2023-2024 | Jardiance |
| Medacta USA, INC. | $288.38 | 2025 | Gmk Sphere, Spherika |
| Novartis Pharmaceuticals Corporation | $270.32 | 2023-2025 | |
| Atricure, INC. | $263.17 | 2023-2025 | Atriclip Laa Exclusion System |
| Shockwave Medical, INC | $222.94 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $176.79 | 2023-2025 | Lifevest |
| Novo Nordisk INC | $94.86 | 2024-2025 | Ozempic, Wegovy |
| Alnylam Pharmaceuticals INC. | $93.19 | 2023-2025 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $88.02 | 2024 | Farxiga, Wainua |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $79.27 | 2023-2024 | |
| Cardiva Medical, INC. | $68.53 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Merck Sharp & Dohme LLC | $68.38 | 2023-2025 | Verquvo |
| Scpharmaceuticals INC. | $66.97 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $54.47 | 2023-2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $46.94 | 2023-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $31.49 | 2024 | Assure Wcd |
| Lilly USA, LLC | $19.39 | 2024 | Jardiance, Zepbound |
| Regeneron Healthcare Solutions, INC. | $18.00 | 2025 | Evkeeza |
| Lexicon Pharmaceuticals, INC. | $16.60 | 2023 | Inpefa |
| Irhythm Technologies, INC. | $15.53 | 2024 | Zio Monitor, Zio Xt Patch |
| Amgen INC. | $14.99 | 2024 | Repatha |
| Zoll Respicardia, INC. | $14.20 | 2025 | Remede System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.